International Scholarly Research Notices / 2015 / Article / Tab 3

Research Article

Assessment of Tachykinin Receptor 3′ Gene Polymorphism rs3733631 in Rosacea

Table 3

(a) Distribution of genotypes among patients with ET rosacea and healthy controls. (b) Distribution of genotypes among patients with PP rosacea and healthy controls.
(a)

ControlsETOR95% CI value

Total
 Genotype
  C/C106 (87.7)65 (97.0)Ref.
  C/G14 (11.6)1 (1.5)0.120.02–0.930.043
  G/G1 (0.8)1 (1.5)1.720.11–28.250.704
 Recessive model
  C/C106 (87.7)65 (97.0)Ref.
  C/G or G/G15 (12.4)2 (3.0)0.220.05–1.010.052
 Allele contrast
  C226 (93.4)131 (97.8)Ref.
  G16 (6.6)3 (2.2)0.330.10–1.170.087

Males
 Genotype
  C/C47 (87.0)23 (92.0)Ref.
  C/G7 (13.0)1 (4.0)0.310.04–2.680.285
  G/G0 (0.0)1 (4.0)
 Recessive model
  C/C47 (87.0)23 (92.0)Ref.
  C/G or G/G7 (13.0)2 (8.0)0.620.12–3.260.57
 Allele contrast
  C101 (93.5)47 (94.0)Ref.
  G7 (6.5)3 (6.0)0.970.24–3.950.966

Females
 Genotype
  C/C59 (88.1)42 (100.0)
  C/G7 (10.4)0 (0.0)
  G/G1 (1.5)0 (0.0)
 Recessive model
  C/C59 (88.1)42 (100.0)
  C/G or G/G8 (11.9)0 (0.0)
 Allele contrast
  C125 (93.3)84 (100.0)
  G9 (6.7)0 (0.0)

Note: statistical significance for differences in genotype, G-containing genotype, and allelic frequencies between patients with ET rosacea and healthy controls: (i) = 6.089, df = 2, and = 0.048; = 4.644, df = 1, and = 0.031; = 3.437, df = 1, and = 0.064 among the entire cohort; (ii) = 3.563, df = 2, and = 0.168; = 0.417, df = 1, and = 0.518; = 0.013, df = 1, and = 0.908 among males; (iii) = 5.412, df = 2, and = 0.067; = 5.412, df = 1, and = 0.020; = 5.885, df = 1, and = 0.014 among females. Data are number of subjects and percentage (%); adjusted for age and gender.
(b)

ControlsPPOR95% CI value

Total
 Genotype
  C/C106 (87.7)43 (70.5)Ref.
  C/G14 (11.6)16 (26.2)2.811.26–6.270.011
  G/G1 (0.8)2 (3.3)50.44–56.980.195
 Recessive model
  C/C106 (87.7)43 (70.5)Ref.
  C/G or G/G15 (12.4)18 (29.5)2.961.37–6.410.006
 Allele contrast
  C226 (93.4)102 (83.6)Ref.
  G16 (6.6)20 (16.4)2.771.38–5.570.004

Males
 Genotype
  C/C47 (87.0)18 (64.3)Ref.
  C/G7 (13.0)8 (28.6)2.940.93–9.320.067
  G/G0 (0.0)2 (7.1)
 Recessive model
  C/C47 (87.0)18 (64.3)Ref.
  C/G or G/G7 (13.0)10 (35.7)3.71.22–11.220.021
 Allele contrast
  C101 (93.5)44 (78.6)Ref.
  G7 (6.5)12 (21.4)3.91.44–10.590.008

Females
 Genotype
  C/C59 (88.1)25 (75.8)Ref.
  C/G7 (10.4)8 (24.2)2.70.88–8.240.082
  G/G1 (1.5)0 (0.0)
 Recessive model
  C/C59 (88.1)25 (75.8)Ref.
  C/G or G/G8 (11.9)8 (24.2)2.360.80–7.010.121
 Allele contrast
  C125 (93.3)58 (87.9)Ref.
  G9 (6.7) 8 (12.1)1.920.70–5.220.204

Note: statistical significance for differences in genotype, G-containing genotype, and allelic frequencies between patients with PP rosacea and healthy controls: (i) = 8.217, df = 2, and = 0.016; = 7.999, df = 1, and = 0.005; = 8.709, df = 1, and = 0.003 among the entire cohort; (ii) = 7.517, df = 2, and = 0.023; = 5.808, df = 1, and = 0.016; = 8.044, df = 1, and = 0.005 among males; (iii) = 3.696, df = 2, and = 0.158; = 2.490, df = 1, and = 0.115; = 1.661, df = 1, and = 0.197 among females. Data are number of subjects and percentage (%); adjusted for age and gender.